Sanofi and Regeneron’s Libtayo (cemiplimab-rwlc), an anti-programmed cell death protein 1 (anti-PD-1) agent, was approved in September 2018 as an immuno-oncology (IO) drug for cutaneous squamous cell carcinoma (CSCC), which is the second most common type of cancer across the US. The drug became the sixth anti-programmed death protein 1/anti-programmed death-ligand 1 (anti-PD-1/anti-PD-L1) agent to breakthrough into the market.
In April 2020, the partnership announced that the Phase III trial of the drug to treat newly diagnosed non-small cell lung cancer (NSCLC) patients met its primary endpoints. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
